Pemafibrate 18971 Smiles: C[C@@]12C[C@@H](CC([C@H]1CC[C@@]13C[C@@H](CC[C@@H]21)C(=C)[C@@H]3O)C(O)=O)O[C@@H]1O[C@H](CO)[C@@H](OS(=O)(=O)O[K])[C@H](OS(=O)(=O)O[K])[C@H]1OC(=O)CC(C)C

Smiles: C[C@@]12C[C@@H](CC([C@H]1CC[C@@]13C[C@@H](CC[C@@H]21)C(=C)[C@@H]3O)C(O)=O)O[C@@H]1O[C@H](CO)[C@@H](OS(=O)(=O)O[K])[C@H](OS(=O)(=O)O[K])[C@H]1OC(=O)CC(C)C

InChi: InChI=1S/C63H113N11O12/c1-26-27-28-41(16)53(76)52-57(80)67-49(38(10)11)61(84)68(19)33-48(75)69(20)44(29-34(2)3)56(79)66-50(39(12)13)62(85)70(21)45(30-35(4)5)55(78)64-42(17)54(77)65-43(18)58(81)71(22)46(31-36(6)7)59(82)72(23)47(32-37(8)9)60(83)73(24)51(40(14)15)63(86)74(52)25/h26-27

InChiKey: OMGLGPKQUFSRNN-UHFFFAOYSA-N

Pretreatment with L-carnitine augments Nrf2 nuclear translocation

These experiments reveal that (+)-Dihydrexidine -triggered induction of the immediate early genes

Pemafibrate 18971 Smiles: C[C@@]12C[C@@H](CC([C@H]1CC[C@@]13C[C@@H](CC[C@@H]21)C(=C)[C@@H]3O)C(O)=O)O[C@@H]1O[C@H](CO)[C@@H](OS(=O)(=O)O[K])[C@H](OS(=O)(=O)O[K])[C@H]1OC(=O)CC(C)CPemafibrate is a potent PPAR agonist, with EC50s of 1 nM, 1. 10 uM and 1. 58 uM for h PPAR, h PPAR and h PPAR, respectively, and possesses lipid lowering effect. Pemafibrate is a potent PPAR agonist, with EC50s of 1 nM, 1. 10 uM and 1. 58 uM for h PPAR, h PPAR and h PPAR, respectively. Pemafibrate is more than 1000 fold selective towards PPAR than PPAR and PPAR. Pemafibrate (3 mg kg, p. o.) increases plasma h apoA I in human apoA I (h apoA I)